The Use of Positron Emission Tomography with [₁₈F] 2-Fluoro-_d-2-Deoxyglucose (FDG-PET) in Hodgkin and Non-Hodgkin's Lymphoma

References

• Hoh, C.K., Schiepers, C., Seltzer, M.A., et al. (1997) "PET in oncology: will it replace the other modalities?", Semin. Nucl. Med. 27, 94–106.
   PubMed Web of Science ®Google Scholar
• Delbeke, D. (1999) "Oncological applications of FDG PET imaging brain tumors, colorectal cancer, Lymphoma and melanoma", J. Nucl. Med. 40, 591–603.
   PubMed Web of Science ®Google Scholar
• Bekerman, C., Hoffer, P.B. and Bitran, J.D. (1984) "The role of gallium-67 in the clinical evaluation of cancer", Semin. Nucl. Med. 14, 296–323.
   PubMed Web of Science ®Google Scholar
• Front, D., Israel, O., Epelbaum, R., et al. (1990) "Ga-67 SPECT before and after treatment of lymphoma", Radiology 175, 515–519.
   PubMed Web of Science ®Google Scholar
• Front, D. and Israel, O. (1995) "The role of Go-67 scintigraphy in evaluating the results of therapy of lymphoma patients", Semin. Nucl. Med. 25, 60–71.
   PubMed Web of Science ®Google Scholar
• Front, D. and Israel, O. (1996) "Present state and future role of gallium-67 scintigraphy in lymphoma", J. Nucl. Med. 37, 530–532.
   PubMed Web of Science ®Google Scholar
• Front, D., Bar-Shalom, R. and Israel, O. (1997) "The continuing clinical role of gallium 67 scintigraphy in the age of receptor imaging", Semin. Nucl. Med. 27, 68–74.
   PubMed Web of Science ®Google Scholar
• Paul, R. (1987) "Comparison of fluorine-18-2-fluorodeoxy-glucose and gallium-67 citrate imaging for detection of lymphoma", J. Nucl. Med. 28, 288–292.
   PubMed Web of Science ®Google Scholar
• Hoh, C.K., Glaspy, J., Rosen, P., et al. (1997) "Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma", J. Nucl. Med. 38, 343–348.
   PubMed Web of Science ®Google Scholar
• Moog, F., Bangerter, M., Diederichs, CC., et al. (1997) "Lym-phoma: role of whole-body 2-deoxy-2 [F-18] fluoro-D-glucose (FDG) PET in nodal staging", Radiology 203, 795–800.
   PubMed Web of Science ®Google Scholar
• Stumpe, K.D., Urbinelli, M., Steinert, H.C., et al. (1998) "Whole-body positron emission tomography using fluoro-deoxyglucose for staging lymphoma: effectiveness and comparison with computed tomography", Fur. J. Nucl. Med. 25, 721–728.
   Web of Science ®Google Scholar
• Moog, E, Bangerter, M., Diederichs, C.G., et al. (1998) "Extranodal malignant lymphoma: detection with FDG-PET versus CT", Radiology 206, 475–481.
   PubMed Web of Science ®Google Scholar
• Buchmann, I., Reinhardt, M., Elsner, K., et al. (2001) "2-(Fluorine-18) fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial", Cancer 91, 889–899.
   PubMed Web of Science ®Google Scholar
• Moog, E, Bangerter, M., Kotzerke, J., et al. (1998) "18-F-fluorodeoxyglucose positron emission tomography as a new approach to detect lymphomatous bone marrow", J. Clin. Oncol. 16, 603–609.
   PubMed Web of Science ®Google Scholar
• Carr, R., Barrington, S.F., Madan, B., et al. (1998) "Detection of lymphoma in bone marrow by whole-body positron emission tomography", Blood 91, 3340–3346.
   PubMed Web of Science ®Google Scholar
• Partridge, S., Timothy, A., O'Doherty, M.J., et al. (2000) "2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution", Ann. Oncol. 11, 1273–1279.
   PubMed Web of Science ®Google Scholar
• Moog, E, Kotzerke, J. and Reske, S.N. (1999) "FDG-PET can replace bone scintigraphy in primary staging of malignant lymphoma", J. Nucl. Med. 40, 1407–1413.
   PubMed Web of Science ®Google Scholar
• Jerusalem, J., Beguin, Y, Fassotte, ME, et al. (2001) "Whole-body positron emission tomography using 18F-fluorodeoxy-glucose compared to standard procedures for staging patients with Hodgkin's disease", Haematologica 86, 266–273.
   PubMed Web of Science ®Google Scholar
• Schoder, H., Meta, J., Yap, C., et al. (2001) "Effect of whole-body (18)F-FDG-PET imaging on clinical staging and management of patients with malignant lymphoma", J. Nucl. Med. 42, 1139–1143.
   PubMed Web of Science ®Google Scholar
• Jerusalem, G., Beguin, Y, Najjar, F., et al. (2001) "Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL)", Ann. Oncol. 12, 825–830.
   PubMed Web of Science ®Google Scholar
• Jerusalem, G. and Beguin, Y.P. (2002) "Positron emission tomography in non-Hodgkin's lymphoma (NHL): relation-ship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL", Clin. Lymphoma 3, 56–61.
   PubMedGoogle Scholar
• Jerusalem, G., Warland, V, Najjar, F., et al. (1999) "Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma", Nucl. Med. Commun. 20, 13–20.
   PubMed Web of Science ®Google Scholar
• Canellos, G.P. (1988) "Residual mass in lymphoma may not be residual disease", J. Clin. Oncol. 6, 931–933.
   PubMed Web of Science ®Google Scholar
• Lowe, V. and Wiseman, G.A. (2002) "Assessment of lymphoma therapy using 18F-FDG PET", J. Nucl. Med. 43, 1028–1030.
   PubMed Web of Science ®Google Scholar
• Hoskin, P. (2002) "FDG-PET in the management of lymphoma: a clinical perspective", Fur. J. Nucl. Med. 29, 449–451.
   Web of Science ®Google Scholar
• Segall, G. (2001) "FDG-PET imaging in patients with lymphoma: a clinical perspective", J. Nucl. Med. 42, 609–610.
   PubMed Web of Science ®Google Scholar
• DeWit, M., Bumann, D., Beyer, W., Herbst, K., et al. (1997) "Whole-body PET for diagnosis of residual mass in patients with lymphoma", Ann. Oncol. 8, 57–60.
   Web of Science ®Google Scholar
• Cremerius, U., Fabry, U., Neuerburg, J., et al. (1998) "Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma", Nucl. Med. Commun. 19, 1055–1063.
   PubMed Web of Science ®Google Scholar
• Bangerter, M., Kotzerke, J., Griesshammer, M., et al. (1999) "Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest", Acta Oncol. 38, 799–804.
   PubMed Web of Science ®Google Scholar
• Bangerter, M., Moog, F., Griesshammer, M., et al. (1999) "Role of whole-body FDG-PET imaging in predicting relapse of malignant lymphoma in patients with residual masses after treatment", Radiography 5, 155–163.
   Google Scholar
• Hueltenschmidt, B., Sautter-Bihl, MI., Lang, O., et al. (2001) "Whole body positron emission tomography in the treatment of Hodgkin disease", Cancer 91, 302–310.
   PubMed Web of Science ®Google Scholar
• Jerusalem, G., Beguin, Y, Fassotte, ME, et al. (1999) "Whole body positron emission tomography using 18F-fluorodeoxy-glucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging", Blood 94, 429–433.
   PubMed Web of Science ®Google Scholar
• Maisey, N., Hill, M., Webb, A., et al. (2000) "Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?", Fur. J. Cancer 26, 200–206.
   Google Scholar
• Jerusalem, G., Beguin, Y., Fassotte, M.F., et al. (2000) "Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma", Haematologica 85, 613–618.
   PubMed Web of Science ®Google Scholar
• Spaepen, K., Stroobants, S., Dupont, P., et al. (2001) "Can positron emission tomography with (18F)-fluorodeoxyglucose after first line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity", Br. J. Haematol. 15, 272–278.
   Google Scholar
• Spaepen, K., Stroobants, S., Dupont, P., et al. (2001) "Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxy ([18F]FDG-PET) after first line chemotherapy in non Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?", J. Gin. Oncol. 19, 414–419.
   Web of Science ®Google Scholar
• Naumarm, R., Vaic, A., Beuthien-Baumann, B., et al. (2001) "Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma", Br. J. Haematol. 115, 793–800.
   PubMed Web of Science ®Google Scholar
• Weihrauch, M., Re, D., Scheidhauer, K., et al. (2001) "Thoracic positron emission tomography using F18-FDG for the evaluation of residual mediastinal Hodgkin disease", Blood 98, 2930–2934.
   PubMed Web of Science ®Google Scholar
• Becherer, A., Mitterbauer, M., Jaeger, U., et al. (2002) "Positron emission tomography with (18F) 2-fluoro-o-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation", Leukemia 16, 260–267.
   PubMed Web of Science ®Google Scholar
• De Wit, M., Bohuslavizki, K.H., Buchert, R., et al. (2001) "18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma", Ann. Oncol. 12, 29–37.
   PubMed Web of Science ®Google Scholar
• Zinzani, P.L., Magagnoli, M., Chierighetti, E, et al. (1999) "The role of positron emission tomography (PET) in the management of lymphoma patients", Ann. Oncol. 10, 1181–1184.
   PubMed Web of Science ®Google Scholar
• Mikhaeel, N.G., Timothy, A.R., Odoherty, M.J., et al. (2000) "18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma, comparison with CT", Leuk. Lymphoma 39, 543–553.
   PubMed Web of Science ®Google Scholar
• Mikhaeel, N.G., Mainwaring, P., Nunan, T. and Timothy, A.R. (2002) "Prognostic value of interim and post treatment FDG-PET scanning in Hodgkin lymphoma [abstract]", Ann. Oncol. 13\(Suppl. 2), 21.
   Google Scholar
• Armitage, J., Weisenburger, D., Hutchins, M., et al. (1986) "Chemotherapy for diffuse large cell lymphoma-rapidly responding patients have more durable remissions", J. Clin. Oncol. 4, 160–164.
   PubMed Web of Science ®Google Scholar
• Spaepen, K., Stroobants, S., Dupont, P., et al. (2002) "Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma", Ann. Oncol. 13, 1356–1363.
   PubMed Web of Science ®Google Scholar
• Filmont, J.E., Yap, C., Emmanouilides, C., et al. (2002) "Prognostic value 18F-FDG-PET after high dose chemo-therapy and prior to autologous stem cell transplantation in lymphoma [abstract]", J. Nucl. Med. 43(suppl), 78P.
   Google Scholar
• Cremerius, U., Fabry, U., Wildberger, J.E., et al. (2002) "Pre-transplant positron emission tomography using fluor-ine-18-fluoro-deoxyglucose predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma", Bone Marrow Transplant. 30, 103–111.
   PubMed Web of Science ®Google Scholar
• Schot, B.W., Pruim, J., van Imhoff, G.W., et al. (2002) "Early FDG-PET for the prediction of long-term outcome in chemo-sensitive relapsed lymphoma [abstract]", Fur. J. Nucl. Med. 29\(Suppl. 1), S113.
   Google Scholar
• Spaepen, K., Stroobants, S., Dupont, P., et al. (2003) "Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high dose chemotherapy and stem cell translantation", Blood 102, 53–59.
   PubMed Web of Science ®Google Scholar
• O'Doherty, M.J., MacDonald, E. and Barrington, S.F. (2002) "Positron emission tomography in the management of lymphomas", Clin. Oncol. 14, 415–426.
   Web of Science ®Google Scholar
• Larcos, G. and Maisey, MN. (1996) "FDG-PET screening for cerebral metastases in patients with suspected malignancy", Nucl. Med. Commun. 17, 197–198.
   PubMed Web of Science ®Google Scholar
• Barrington, S.F. and Maisey, M.N. (1996) "Skeletal muscle uptake of fluorine-18-FDG: effect of oral diazepam", J. Nucl. Med. 37, 1127–1129.
   PubMed Web of Science ®Google Scholar
• Nakahara, T., Fujii, H., Ide, M., et al. (2001) "FDG uptake in the morphologically normal thymus: comparison of FDG positron emission tomography and CT Br", J. Radiol. 74, 821–824.
   Google Scholar
• Brink, I., Reinhardt, M., Hoegerle, S., et al. (2001) "Increased metabolic activity in the thymus gland studied with 18F-FDG PET: age dependency and frequency after chemotherapy", J. Nucl. Med. 42, 591–595.
   PubMed Web of Science ®Google Scholar
• Alibazoglu, H., Alibazoglu, B., Hollinger, E.F., et al. (1999) "Normal thymic uptake of 2-deoxy-2[F-18] fluoro-o-glucose", Gin. Nucl. Med. 24, 597–600.
   Web of Science ®Google Scholar
• Bakheet, S. and Powe, J. (1998) "Benign causes of 18-FDG uptake on whole body imaging", Semin. Nucl. Med. 28, 352–358.
   PubMed Web of Science ®Google Scholar